Literature DB >> 9653896

Are high-affinity progesterone binding site(s) from porcine liver microsomes members of the sigma receptor family?

C Meyer1, K Schmieding, E Falkenstein, M Wehling.   

Abstract

Membrane progesterone binding sites have been purified recently from pig liver. Since progesterone is considered as an endogenous sigma (sigma) receptor ligand, these sites were characterized pharmacologically by ligands selective for sigma receptor and dopamine receptor binding sites, and by other drugs from distinct pharmacological classes. Binding studies using the radioligand [3H]progesterone were done in crude membrane preparations and solubilized fractions to determine half-maximal inhibitory concentration (IC50) values, from which inhibitory constants (Ki values) were calculated. Radioligand binding was inhibited by the sigma receptor ligands haloperidol, carbetapentane citrate, 1,3-Di(2-tolyl)guanidine (DTG), R(-)-N-(3-phenyl-1-propyl)-1-phenyl-2 aminopropane HCl (R(-)-PPAAP HCl), or sigma receptor antagonists like (+)-3-(3-hydroxyphenyl)-N-propylpiperidine HCl (R(+)-PPP HCl) and cis-9-[3-(3,5-dimethyl-1-piperazinyl)propyl]-9H-carbazole dihydrochloride (rimcazole 2HCl). The hierarchy of inhibitory action was not fully compatible with either sigma receptor class I (moderate affinity of pentazocine, diphenylhydantoin (phenytoin) insensitivity) or II sites (high affinity of carbetapentane). The data thus suggest that progesterone binding sites in porcine liver membranes are related to the sigma receptor binding site superfamily, but may represent a particular species with progesterone specificity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653896     DOI: 10.1016/s0014-2999(98)00103-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

2.  Progesterone inhibits apoptosis in part by PGRMC1-regulated gene expression.

Authors:  J J Peluso; X Liu; A Gawkowska; V Lodde; C A Wu
Journal:  Mol Cell Endocrinol       Date:  2010-02-06       Impact factor: 4.102

Review 3.  PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding.

Authors:  Hannah J Rohe; Ikhlas S Ahmed; Katherine E Twist; Rolf J Craven
Journal:  Pharmacol Ther       Date:  2008-11-01       Impact factor: 12.310

Review 4.  Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions.

Authors:  Peter Thomas
Journal:  Front Neuroendocrinol       Date:  2008-02-01       Impact factor: 8.606

5.  Enhancement of cell surface expression and receptor functions of membrane progestin receptor α (mPRα) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors.

Authors:  Peter Thomas; Yefei Pang; Jing Dong
Journal:  Endocrinology       Date:  2014-01-01       Impact factor: 4.736

Review 6.  The σ2 receptor: a novel protein for the imaging and treatment of cancer.

Authors:  Robert H Mach; Chenbo Zeng; William G Hawkins
Journal:  J Med Chem       Date:  2013-06-18       Impact factor: 7.446

7.  Antitussive activity of sigma-1 receptor agonists in the guinea-pig.

Authors:  Claire Brown; Malika Fezoui; William M Selig; Carl E Schwartz; James L Ellis
Journal:  Br J Pharmacol       Date:  2003-12-22       Impact factor: 8.739

8.  Pathways driving the endocytosis of mutant and wild-type EGFR in cancer.

Authors:  Kaia K Hampton; Rolf J Craven
Journal:  Oncoscience       Date:  2014-07-29

9.  Revealing genes associated with vitellogenesis in the liver of the zebrafish (Danio rerio) by transcriptome profiling.

Authors:  Liraz Levi; Irena Pekarski; Ellen Gutman; Paolo Fortina; Terry Hyslop; Jakob Biran; Berta Levavi-Sivan; Esther Lubzens
Journal:  BMC Genomics       Date:  2009-03-31       Impact factor: 3.969

10.  Low affinity glucocorticoid binding site ligands as potential anti-fibrogenics.

Authors:  Carylyn J Marek; Karen Wallace; Elaine Durward; Matthew Koruth; Val Leel; Lucy J Leiper; Matthew C Wright
Journal:  Comp Hepatol       Date:  2009-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.